Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIO-KRK-0207 maintenance strategy trial in metastatic colorectal cancer
2008-007974-39Phase 3Completed
- Sponsor
- AIO-Studien
- Start
- Mar 2009
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bevacizumab, capecitabine, fluorouracil, folinic acid and oxaliplatin in metastatic colorectal adenocarcinoma (mCRC) (3 arms), sponsored by AIO-Studien. Primary endpoint: Time to failure of maintenance and reinduction treatment strategy. Started Mar 2009; status: completed.
02
Drugs
bevacizumabcapecitabinefluorouracilfolinic acidoxaliplatin
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2008-007974-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007974-39.